Atomo Diagnostics Ltd.
AASX:AT10.02
AUD
+0.00
(-5.56%)
ISIN
AU0000080327
Return %
Stock
S&P 500
1Y
-37.04
14.20
3Y
-26.09
81.12
5Y
-95.28
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Cheri L. Walker
- Full Time Employees
- 85
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 3-5 George St Leichardt NSW Australia 2040
- IPO Date
- Apr 16, 2020
- Website
- atomodiagnostics.com
- Similar Companies
- Business
- Atomo Diagnostics Limited (ASX:AT1) manufactures and supplies innovative, user-centered rapid diagnostic test (RDT) devices for point-of-care and self-testing applications worldwide. The company offers its patented AtomoRapid platforms, including the Galileo, Pascal, and Elion cassettes, which simplify blood-based testing procedures, reduce user errors by up to 90% in blood delivery and 100% in buffer delivery, and shorten procedure times by 40%; core products encompass HIV self-tests with 99.6% accuracy delivering results in 15 minutes, NG Biotech Precision+ blood-based pregnancy tests for professional and at-home use, Lumos Diagnostics FebriDx on the Pascal platform for distinguishing viral versus bacterial respiratory infections with 99% accuracy and FDA 510(k) clearance, as well as tests for active syphilis, viral versus bacterial differentiation, and other infectious diseases. Founded in 2010 and headquartered in Leichhardt, Australia, with offices in South Africa and the United Kingdom, Atomo operates globally with products registered in over 40 countries, including WHO prequalification for the Galileo platform and CE marking for Pascal and Galileo platforms; it serves professional healthcare providers, over-the-counter channels, and self-testers through supply agreements with partners like Newfoundland Diagnostics, NG Biotech, and Lumos Diagnostics. Recent developments include a July 2025 placement of $727,612 from its Share Purchase Plan shortfall to sophisticated investors, raising additional capital alongside $272,387 from the SPP for working capital and business objectives; in April 2025, the company launched a $3.1 million capital raise via placement and SPP amid a strategic overhaul, board restructuring, and operational cost efficiencies; Q2 FY24 activities featured over 50,000 units sold to existing customers, new purchase orders for Elion cassette assessments with reader systems, anticipated agreements with Australian entities for blood- and swab-based tests, HIV self-test expansions into Germany via MePro pharmacies and Colombia regulatory submissions, and progressing TGA approvals for blood pregnancy tests with NG Biotech partner TOWA Pharmaceutical.
Company News
Atomo Diagnostics Q2 Earnings Call Highlights